Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Research and Innovation Action · Running

ACT4KIDS-TB Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children

Coordinator
Instituut Voor Tropische Geneeskunde, Belgium
Runs
1 August 2026 to 31 July 2030
Status
Running
EU funding
€2.1m
Total cost
€2.5m
Partners
6 organisations in 4 countries
Type
Research and Innovation Action
Grant agreement
101248873

What the project is doing

In the project's own words, from its summary on CORDIS.

ACT4KIDS-TB aims at closing the diagnostic gap for paediatric tuberculosis (TB) with a novel pioneering clinical decision-making (CDM)-app incorporating two transformative innovations (three-in-one): Actiphage and computer assisted diagnosis of CXRs (CAD) at the point-of-care (POC). ACT4KIDS-TB will be the first to determine the diagnostic yield of Actiphage, a repurposed bacteriophage-based PCR assay for blood in children.

Actiphage detects viable mycobacteria within hours of sampling & with simplified laboratory requirements versus culture. ACT4KIDS-TB will also externally validate available paediatric CAD algorithms, including smartphone-based CXR images, which will evaluate performance at point-of-care via a new CAD-POC-app. The CDM-app will incorporate results from Actiphage, the CAD POC-app, patient characteristics & features of the setting to provide clinicians with a point-of-care, on-& offline, post-test TB probability to guide treatment decisions.

ACT4KIDS-TB will recruit 206 children with presumptive TB as well as up to 150 health-care-workers and caregivers in South Africa & Benin, two high-TB burden settings. ACT4KIDS-TB includes robust cost-effectiveness, acceptability & feasibility studies for a clear technology transfer roadmap. ACT4KIDS-TB will add South-South capacity strengthening by providing two Sub-Saharan African PhDs & developing Open Access trainings for paediatric TB diagnosis.

A diverse group of stakeholders facilitates intra-African collaborations; regional manufacturing & support translating research into policy & practice and technology scale-up. These stakeholders comprise industry (e.g. Delft Imaging), policy makers (WHO, Africa CDC, TEI-MAV+, …) as well as global scientific entities (WSPID, WARN-CARN-TB network…) ACT4KIDS-TB will transform paediatric TB with faster, low-resource, more accessible & cost-effective diagnostics using innovative technologies for a vulnerable population; young children in high-burden settings.

Who is involved

OrganisationCityCountryRole
Instituut Voor Tropische GeneeskundeAntwerpenBelgiumCoordinator
Centre National Hospitalier De Pneumo-PhtisiologieCotonouBJParticipant
Aga Khan University KenyaNairobiKenyaParticipant
Health Research Operations Kenya LimitedKilifiKenyaParticipant
Stellenbosch UniversityStellenboschSouth AfricaParticipant
University of Cape TownRondeboschSouth AfricaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI